Randomized Controlled Trial
doi: 10.2196/jmir.6414. A Mobile App to Stabilize Daily Functional Activity of Breast Cancer Patients in Collaboration With the Physician: A Randomized Controlled Clinical TrialAffiliations
AffiliationItem in Clipboard
Randomized Controlled Trial
A Mobile App to Stabilize Daily Functional Activity of Breast Cancer Patients in Collaboration With the Physician: A Randomized Controlled Clinical TrialMarco Egbring et al. J Med Internet Res. 2016.
AffiliationItem in Clipboard
AbstractBackground: The well-being of breast cancer patients and reporting of adverse events require close monitoring. Mobile apps allow continuous recording of disease- and medication-related symptoms in patients undergoing chemotherapy.
Objective: The aim of the study was to evaluate the effects of a mobile app on patient-reported daily functional activity in a supervised and unsupervised setting.
Methods: We conducted a randomized controlled study of 139 breast cancer patients undergoing chemotherapy. Patient status was self-measured using Eastern Cooperative Oncology Group scoring and Common Terminology Criteria for Adverse Events. Participants were randomly assigned to a control group, an unsupervised group that used a mobile app to record data, or a supervised group that used the app and reviewed data with a physician. Primary outcome variables were change in daily functional activity and symptoms over three outpatient visits.
Results: Functional activity scores declined in all groups from the first to second visit. However, from the second to third visit, only the supervised group improved, whereas the others continued to decline. Overall, the supervised group showed no significant difference from the first (median 90.85, IQR 30.67) to third visit (median 84.76, IQR 18.29, P=.72). Both app-using groups reported more distinct adverse events in the app than in the questionnaire (supervised: n=1033 vs n=656; unsupervised: n=852 vs n=823), although the unsupervised group reported more symptoms overall (n=4808) in the app than the supervised group (n=4463).
Conclusions: The mobile app was associated with stabilized daily functional activity when used under collaborative review. App-using participants could more frequently report adverse events, and those under supervision made fewer and more precise entries than unsupervised participants. Our findings suggest that patient well-being and awareness of chemotherapy adverse effects can be improved by using a mobile app in collaboration with the treating physician.
Clinicaltrial: ClinicalTrials.gov NCT02004496; https://clinicaltrials.gov/ct2/show/NCT02004496 (Archived by WebCite at http://www.webcitation.org/6k68FZHo2).
Keywords: breast cancer; breast neoplasms; collaboration; daily functional activity; mobile app.
Conflict of interest statementConflicts of Interest: None declared.
FiguresFigure 1
CONSORT diagram demonstrating the flow…
Figure 1
CONSORT diagram demonstrating the flow of patients.
Figure 1CONSORT diagram demonstrating the flow of patients.
Figure 2
Visual analog scale for current…
Figure 2
Visual analog scale for current and worst daily functional activity in the questionnaire.
Figure 2Visual analog scale for current and worst daily functional activity in the questionnaire.
Figure 3
Participants who used the Internet…
Figure 3
Participants who used the Internet to obtain disease-specific information.
Figure 3Participants who used the Internet to obtain disease-specific information.
Similar articlesTrojan A, Bättig B, Mannhart M, Seifert B, Brauchbar MN, Egbring M. Trojan A, et al. JMIR Cancer. 2021 Mar 17;7(1):e26950. doi: 10.2196/26950. JMIR Cancer. 2021. PMID: 33729162 Free PMC article.
Kim HJ, Kim SM, Shin H, Jang JS, Kim YI, Han DH. Kim HJ, et al. J Med Internet Res. 2018 Oct 29;20(10):e273. doi: 10.2196/jmir.9559. J Med Internet Res. 2018. PMID: 30578205 Free PMC article. Clinical Trial.
Armstrong KA, Coyte PC, Bhatia RS, Semple JL. Armstrong KA, et al. JMIR Res Protoc. 2015 Jun 3;4(2):e65. doi: 10.2196/resprot.4352. JMIR Res Protoc. 2015. PMID: 26040252 Free PMC article.
Rincon E, Monteiro-Guerra F, Rivera-Romero O, Dorronzoro-Zubiete E, Sanchez-Bocanegra CL, Gabarron E. Rincon E, et al. JMIR Mhealth Uhealth. 2017 Dec 4;5(12):e187. doi: 10.2196/mhealth.8741. JMIR Mhealth Uhealth. 2017. PMID: 29203459 Free PMC article. Review.
Warmerdam E, Hausdorff JM, Atrsaei A, Zhou Y, Mirelman A, Aminian K, Espay AJ, Hansen C, Evers LJW, Keller A, Lamoth C, Pilotto A, Rochester L, Schmidt G, Bloem BR, Maetzler W. Warmerdam E, et al. Lancet Neurol. 2020 May;19(5):462-470. doi: 10.1016/S1474-4422(19)30397-7. Epub 2020 Feb 11. Lancet Neurol. 2020. PMID: 32059811 Review.
Pircher M, Winder T, Trojan A. Pircher M, et al. Case Rep Oncol. 2021 Mar 29;14(1):616-621. doi: 10.1159/000513905. eCollection 2021 Jan-Apr. Case Rep Oncol. 2021. PMID: 33976643 Free PMC article.
Dhar E, Bah AN, Chicchi Giglioli IA, Quer S, Fernandez-Luque L, Núñez-Benjumea FJ, Malwade S, Uddin M, Upadhyay U, Syed-Abdul S. Dhar E, et al. Cancers (Basel). 2023 Mar 15;15(6):1775. doi: 10.3390/cancers15061775. Cancers (Basel). 2023. PMID: 36980661 Free PMC article.
Trojan A, Bättig B, Mannhart M, Seifert B, Brauchbar MN, Egbring M. Trojan A, et al. JMIR Cancer. 2021 Mar 17;7(1):e26950. doi: 10.2196/26950. JMIR Cancer. 2021. PMID: 33729162 Free PMC article.
Cucciniello M, Petracca F, Ciani O, Tarricone R. Cucciniello M, et al. NPJ Digit Med. 2021 Oct 5;4(1):144. doi: 10.1038/s41746-021-00517-1. NPJ Digit Med. 2021. PMID: 34611287 Free PMC article. Review.
Yamaguchi K, Higashiyama N, Umemiya M, Inayama Y, Koike A, Ueda A, Mizuno R, Taki M, Yamanoi K, Murakami R, Hamanishi J, Mandai M. Yamaguchi K, et al. Int J Clin Oncol. 2025 Jan;30(1):1-16. doi: 10.1007/s10147-024-02651-8. Epub 2024 Nov 16. Int J Clin Oncol. 2025. PMID: 39549219 Free PMC article. Review.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3